首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers.
【24h】

Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers.

机译:原发性肿瘤部位可作为晚期口腔癌明确放疗治疗结果的预测指标。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the outcome of definitive radiotherapy (RT) for oral cavity cancers and to assess prognostic factors. METHODS AND MATERIALS: Definitive RT was performed on 115 patients with oral cavity cancers at Stages III, IVA, and IVB, with a distribution of 6%, 47%, and 47%, respectively. The median dose of RT was 72 Gy (range, 62-76 Gy). Cisplatin-based chemotherapy was administered to 95% of the patients. Eleven patients underwent salvage surgery after RT failure. RESULTS: Eight-eight (76.5%) patients responded partially and 23 (20%) completely; of the patients who responded, 18% and 57%, respectively, experienced a durable effect of treatment. The 3-year overall survival, disease-specific survival, and progression-free survival were 22%, 27%, and 25%, respectively. The 3-year PFS rates based on the primary tumor sites were as follows: Group I (buccal, mouth floor, and gum) 51%, Group II (retromolar and hard palate) 18%, and Group III (tongue and lip) 6% (p < 0.0001). The 3-year progression-free survival was 41% for N0 patients and 19% for patients with N+ disease (p = 0.012). The T stage and RT technique did not affect survival. The patients who underwent salvage surgery demonstrated better 3-year overall survival and disease-specific survival (53% vs. 19%, p = 0.015 and 53% vs. 24%, p = 0.029, respectively). Subsite group, N+, and salvage surgery were the only significant prognostic factors for survival after multivariate analysis. CONCLUSION: The primary tumor site and neck stage are prognostic predictors in advanced-stage oral cancer patients who received radical RT. The primary tumor extension and RT technique did not influence survival.
机译:目的:评估针对口腔癌的明确放疗(RT)的结果并评估预后因素。方法和材料:对115例III,IVA和IVB期口腔癌患者进行了确定性RT,其分布分别为6%,47%和47%。 RT的中位剂量为72 Gy(范围为62-76 Gy)。 95%的患者进行了基于顺铂的化疗。 RT失败后接受挽救手术的11名患者。结果:八十八(76.5%)例患者部分缓解,23例(20%)完全缓解。在有反应的患者中,分别有18%和57%的患者经历了持久的治疗。 3年总生存期,疾病特异性生存期和无进展生存期分别为22%,27%和25%。基于原发性肿瘤部位的3年PFS率如下:第一组(颊,口底和牙龈)51%,第二组(回臼齿和硬pa)18%,第三组(舌和唇)6 %(p <0.0001)。 N0患者的3年无进展生存率为41%,N +疾病患者为19%(p = 0.012)。 T期和RT技术不影响生存。接受抢救手术的患者表现出更好的3年总生存率和疾病特异性生存率(分别为53%vs. 19%,p = 0.015和53%vs. 24%,p = 0.029)。多变量分析后,亚位组,N +和挽救性手术是生存的唯一重要预后因素。结论:原发肿瘤部位和颈部分期是接受根治性放疗的晚期口腔癌患者的预后指标。原发肿瘤的扩展和放疗技术不影响生存。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号